New Deputy Minister of Health highlights the true measure of medical progress in cancer treatment

In a significant shift toward patient-centered care, newly appointed Deputy Minister of Health, Associate Professor Dr. Dao Xuan Co, has challenged the medical community to redefine the metrics of clinical success. Speaking at a national oncology conference held in Hanoi on November 5, Dr. Co argued that while technological advancements and innovative therapies are vital, they must be viewed through the prism of their tangible impact on patient outcomes, accessibility, and quality of life. His remarks underscore a growing recognition that the true value of medical science is not merely in the sophistication of equipment, but in how effectively it extends life and alleviates the burden on those suffering from malignancy.

The Human and Economic Cost of Oncology

Behind every cancer diagnosis lies a complex narrative of familial strain, financial hardship, and psychological distress. Dr. Co emphasized that the emotional and economic weight placed on patients and their families often goes unquantified in clinical reports. For many households in Vietnam, a cancer diagnosis is not only a medical crisis but a catastrophic financial event.

The Deputy Minister pointedly asked the assembly of experts: "How many patients are actually benefiting from these breakthroughs? How many are being detected early enough to receive effective treatment, and how many are living longer with an improved quality of life?" By framing the question this way, the Ministry of Health is signaling a transition from a volume-based success metric—tracking only the number of procedures performed—to an outcome-based metric that prioritizes survival rates and the physical wellbeing of the patient.

Chronology and Escalation of the Cancer Burden

The landscape of oncology in Vietnam has changed dramatically over the last two and a half decades. In the year 2000, national health records indicated approximately 68,000 new cancer cases annually. By the present day, that figure has surged to nearly 180,000 new cases per year, with an associated mortality rate of approximately 120,000 deaths.

This rapid increase, driven by an aging population, changes in lifestyle, and improved diagnostic capabilities, has placed an unprecedented strain on the national health system. The most prevalent forms of the disease—including breast, liver, lung, colorectal, and stomach cancers—continue to account for the majority of these cases. The evolution of this trajectory from 68,000 cases to nearly triple that amount highlights a critical need for a more integrated, proactive approach to healthcare management.

The Economics of Care and Insurance Sustainability

A significant portion of the discourse centered on the financial sustainability of the health insurance fund. In 2022, the Social Health Insurance fund allocated over 6.6 billion VND (14.5% of the total fund) to cancer drugs and immunotherapy. By 2023, this expenditure rose to over 7.5 billion VND (15.8%). Preliminary data for 2025 shows a further escalation to nearly 9.6 billion VND.

These figures illustrate the heavy reliance on the national health insurance system to subsidize modern, often high-cost treatments. Dr. Co stressed that the Ministry is committed to transparency in the allocation of these resources. "Every dong from the state budget, the health insurance fund, and the out-of-pocket payments of citizens must be utilized with transparency, efficiency, and clear purpose," he stated. He emphasized that the introduction of new technologies must be based on evidence-based medicine and rigorous cost-benefit analysis.

Strategic Priorities for Vietnam’s Oncology Network

To address these challenges, the Ministry of Health has outlined a multi-pronged strategy designed to modernize the nation’s cancer care infrastructure:

1. Network Integration: The development of a nationwide oncology network that is synchronous and continuous, ensuring that expertise and resources are shared effectively between central and provincial hospitals.
2. Early Detection and Prevention: Moving the focus of the health system "upstream." Dr. Co argued that the most effective way to improve survival is to prioritize screening programs that detect cancers at stages where they are still curable.
3. Standardized Clinical Pathways: Ensuring that treatment protocols are uniform across the country, reducing the disparity in care quality between urban centers and remote provinces.
4. Professional Ethics and Legal Compliance: A renewed emphasis on the moral obligations of healthcare providers. The Deputy Minister underscored the necessity for medical professionals to remain within the bounds of legal regulations and ethical standards, ensuring that patient welfare remains the primary driver of clinical decisions.

Challenging the Myth of Technological Supremacy

One of the most provocative aspects of Dr. Co’s address was his cautionary note regarding the adoption of new medical technologies. He warned against the "fetishization" of the latest equipment, noting that the most expensive or newest technology is not always the most appropriate for every clinical scenario.

"Not every new technology is the most suitable technology," he remarked. "And not every expensive treatment yields the best outcomes for every patient." This statement suggests that the Ministry will be implementing stricter oversight on the procurement and application of medical devices, favoring those that provide the most proven, sustainable benefit to the largest number of patients.

Implications for the Future

The implications of these policy directions are far-reaching. By advocating for a system that measures success by the patient’s ability to lead a high-quality life, the Ministry of Health is effectively shifting the philosophy of Vietnamese oncology. This approach recognizes that the "gap" in medical geography—the distance between a patient’s home and a high-quality treatment facility—must not be allowed to become a "gap" in survival probability.

The focus on "evidence-based" treatment is expected to lead to more rigorous health technology assessments (HTAs) before new drugs or devices are approved for reimbursement. This is a critical step in managing the rising costs of oncology care while ensuring that the health insurance fund remains solvent and capable of supporting the most vulnerable populations.

As Vietnam moves forward, the success of these reforms will depend on the cooperation between clinical researchers, hospital administrators, and policymakers. The goal is a seamless, integrated system where the patient is not merely a data point in a clinical study, but the central focus of a holistic, compassionate, and economically viable healthcare ecosystem.

In conclusion, the message from the Ministry of Health is clear: while science has advanced, the mandate for the medical community remains the same. The ultimate test of progress is not found in journals or laboratory benchmarks, but in the number of lives saved, the length of time patients spend in remission, and the dignity preserved for those battling the disease. The path ahead requires not only technological brilliance but also administrative wisdom, ethical rigor, and a steadfast commitment to equity in health outcomes.